A MULTI-CENTER, RANDOMIZED, PARALLEL, DOUBLE-BLINDED, DOUBLE-ARM, PLACEBO-CONTROLLED STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF HERB AGERATUM CONYZOIDES IN OIL FORMULATION IN ADULT INDIAN MALES SUBJECTS EXHIBITING ANDROGENIC ALOPECIA (MALE PATTERN BALDNESS).

Gencor Pacific Organics India Pvt Ltd0 个研究点目标入组 80 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male subjects between ages of 18 to 41 years (both years inclusive).
•2.Subjects must be able to be classified under any of the scales of Norwood / Hamilton Scale for menâ??s hair loss.
•3.Subjects who are not using any other hair growth products for the last 30 days.
•4.Subjects should agree to not use any other hair growth products during the study.
•5.Subjects should agree to not to alter their hair style or dye their hair during the study.
•6.Subjects should be able to comply with the study procedures and Schedule.
•7.Subjects should be able to understand study information provided and give informed consent, after being explained by the study team.

•1.Subjects suffering from mycotic infections.
•2.Subjects who have taken radiotherapy to scalp for cancer treatment.
•3.Subjects with a history of systemic malignancy.
•4.Subjects with a history of cutaneous malignancy.
•5.Subjects with Nevi / cutaneous lesion currently.
•6.Subjects with an evidence of an immune-compromised state.
•7.Subjects with poorly controlled diabetes.
•8.Subjects with clinically significant medical complaints.
•9.Subjects with known psychiatric disease.
•10.Subjects with serious local infection (e.g. cellulites, abscess) within 90 days of the signing of the informed consent
•11.Subjects with systemic infection (e.g., pneumonia, septicemia) within 90 days of the signing of the informed consent.
•12.Subjects with known hypothyroidism.
•13.Subjects with known hyperthyroidism.
•14.Subjects with Cicatricial alopecia

发起方

Gencor Pacific Organics India Pvt Ltd